Susceptibility of Multidrug-Resistant Escherichia coli , Klebsiella pneumoniae , and Pseudomonas aeruginosa from Germany to Ceftolozane–Tazobactam, Ceftazidime–Avibactam, and Imipenem–Relebactam
Microbial Drug Resistance · 2023
DOI: 10.1089/mdr.2022.0175 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbial Drug Resistance, 2023. Verfasst von Michael Kresken und 7 weiteren Autor:innen. Beteiligte Einrichtung: Antiinfectives Intelligence GmbH, Cologne, Germany. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Pseudomonas Infections. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 16 Literaturangaben.
Abstract (Originalsprache)
This cross-sectional in-vitro resistance surveillance study involving 10 medical laboratories was conducted in 2018. Each study site was asked to collect 30 consecutive nonduplicate isolates per species from hospitalized patients with documented infections. Minimum inhibitory concentrations were determined at a central laboratory. European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints were used for interpretation. A total of 860 isolates were collected, including 298 Escherichia coli , 268 Klebsiella pneumoniae , and 294 Pseudomonas aeruginosa . Fifty (16.8%) E. coli and 63 (23.5%) K. pneumoniae isolates were found to be resistant to third-generation cephalosporins. Resistance to carbapenems (imipenem and/or meropenem) was identified in 5 (1.9%) K. pneumoniae and 64 (21.8%) P. aeruginosa , but not in E. coli . Thirty-three (11.2%) P. aeruginosa isolates were resistant to both carbapenems and 30 (10.2%) P. aeruginosa showed resistance to ≥3 antimicrobials/antimicrobial groups (among piperacillin–tazobactam, ceftazidime, tobramycin, carbapenems, and fluoroquinolones). The susceptibility rates of these multidrug-resistant (MDR) phenotypes to ceftolozane–tazobactam, ceftazidime–avibactam, and imipenem–relebactam were 70–100%, with the exception of carbapenem-resistant K. pneumoniae . Only two K. pneumoniae and four P. aeruginosa isolates were resistant to all three beta-lactam/beta-lactamase-inhibitor combinations. However, this favorable result should be viewed in light of the relatively low prevalence of MDR organisms that require these agents in Germany.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Antiinfectives Intelligence GmbH, Cologne, Germany.
- Rheinische Fachhochschule Köln gGmbH, Cologne, Germany.
- Institute of Medical Microbiology and Infection Control, University Hospital Frankfurt, Frankfurt am Main, Germany.
- Department of Medical Microbiology, German National Reference Centre for Multidrug-Resistant Gram-Negative Bacteria, Ruhr-University Bochum, Bochum, Germany.
- Faculty of Medicine, Institute for Medical Microbiology, Immunology and Hygiene, University Hospital Cologne, University of Cologne, Cologne, Germany.
Zitieren
APA
Kresken, M., Wohlfarth, E., Wichelhaus, T. A., Gatermann, S. G., Pfennigwerth, N., Eisfeld, J., Seifert, H., & German BL/BLI Study Group (2023). Susceptibility of Multidrug-Resistant Escherichia coli , Klebsiella pneumoniae , and Pseudomonas aeruginosa from Germany to Ceftolozane–Tazobactam, Ceftazidime–Avibactam, and Imipenem–Relebactam. Microbial Drug Resistance. https://doi.org/10.1089/mdr.2022.0175
Vancouver
Kresken M, Wohlfarth E, Wichelhaus TA, Gatermann SG, Pfennigwerth N, Eisfeld J, et al. Susceptibility of Multidrug-Resistant Escherichia coli , Klebsiella pneumoniae , and Pseudomonas aeruginosa from Germany to Ceftolozane–Tazobactam, Ceftazidime–Avibactam, and Imipenem–Relebactam. Microbial Drug Resistance. 2023. doi:10.1089/mdr.2022.0175
BibTeX
@article{Kresken2023,
author = {Kresken, Michael and Wohlfarth, Esther and Wichelhaus, Thomas A and Gatermann, Sören G and Pfennigwerth, Niels and Eisfeld, Jessica and Seifert, Harald and German BL/BLI Study Group, German BL/BLI Study Group},
title = {Susceptibility of Multidrug-Resistant Escherichia coli , Klebsiella pneumoniae , and Pseudomonas aeruginosa from Germany to Ceftolozane–Tazobactam, Ceftazidime–Avibactam, and Imipenem–Relebactam},
journal = {Microbial Drug Resistance},
year = {2023},
doi = {10.1089/mdr.2022.0175}
}
EUVIMED